We found no significant differences in the prevalence of mutations in two other genes of the PI3K-AKT pathway which were previously reported to be linked with a more aggressive tumor behavior, resistance to treatments, and poor prognosis [56,58,59,60,61,62,63]: AKT1 and PTEN, explained by a relatively small sample size in our study. This evidence concerns the gene AKT1 and neoplasm.